AQST
NASDAQ
US
Aquestive Therapeutics, Inc. - Common Stock
$4,13
▲ +$0,00
(+0,00%)
Vol. 914K
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$788.1M
ROE
-21,8%
Margine
-158,8%
D/E
468,25
Beta
1,69
52W
$2–$8
Consenso Wall Street
15 analisti · Apr 20264
Acquisto forte
10
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,3%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 25,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,14
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,14 | — | — |
| Dic 2025 | $-0,14 | $-0,15 | $-0,01 |
| Set 2025 | $-0,14 | $-0,14 | $0,00 |
| Giu 2025 | $-0,17 | $-0,14 | +$0,03 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $11.9M | $8.7M | $10.0M | $12.8M | $13.0M |
| Utile netto | — | -$17.1M | -$22.9M | -$13.5M | -$15.4M | -$31.9M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -21.8% | -21.8% | -21.8% | -21.8% | -21.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -135.4% | -147.4% | -147.4% | -147.4% | -158.8% | -158.8% |
| Gross Margin | 54.4% | 61.1% | 61.1% | 61.1% | 60.3% | 60.3% |
| D/E Ratio | — | 468.25 | 468.25 | 468.25 | 468.25 | 468.25 |
| Current Ratio | 3.53 | 3.53 | 3.53 | 3.53 | 5.93 | 5.93 |
Rapporti chiave
ROA (TTM)
-59,9%
P/S (TTM)
18,16
P/B
15,6
EPS (TTM)
$-0,70
CF/Share
$-0,17
Crescita ricavi 3A
+4,2%
52W High
$7,55
52W Low
$2,12
$2,12
Intervallo 52 settimane
$7,55
Salute finanziaria
Flusso di cassa libero
-$8.6M
Debito netto
-$78.7M
Liquidità
$121.2M
Debito totale
$42.5M
Aggiornato al Dic 31, 2025
Як AQST виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка AQST vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
18,2
▲
267%
sopra
peer
(5,0)
vs Peer
vs Settore
Più costoso
P/B
15,6
▲
635%
sopra
peer
(2,1)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість AQST vs аналоги Pharmaceuticals
ROE
-21,8%
▲
60%
sopra
peer
(-54,3%)
vs Peer
vs Settore
Sotto media
Net margin
-158,8%
▼
235%
sotto
peer
(-47,4%)
vs Peer
vs Settore
Debole
Валова маржа
60,3%
▼
12%
sotto
peer
(68,3%)
vs Peer
vs Settore
Debole
ROA
-59,9%
▼
60%
sotto
peer
(-37,4%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя AQST vs аналоги Pharmaceuticals
D/E ratio
468,3
▲
30306%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
5,9
▲
77%
sopra
peer
(3,4)
vs Peer
vs Settore
Sotto media
Beta
1,7
▲
80%
sopra
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів AQST
AQST
Mediana peer
Industria
AQST прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
AQST vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
TOTH A ERNEST JR
Chief Financial Officer · Mar 10
58254 shs
BARBER DANIEL R
Chief Executive Officer · Mar 10
180677 shs
BOYD PETER E
Officer · Mar 10
29814 shs
BRAENDER LORI J
Officer · Mar 10
40102 shs
JUNG CASSIE
Chief Operating Officer · Mar 10
45791 shs
KORCZYNSKI SHERRY
Officer · Mar 10
15741 shs
CIOFFI MELINA
Officer · Mar 10
25311 shs
TOTH A ERNEST JR
Chief Financial Officer · Mar 09
95000 shs
BARBER DANIEL R
Chief Executive Officer · Mar 09
262000 shs
BOYD PETER E
Officer · Mar 09
80000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 26,51%Bratton Capital Management,…
8,04%
$39.4M
Blackrock Inc.
6,37%
$31.3M
RTW Investments LP
5,12%
$25.1M
Vanguard Group Inc
4,83%
$23.7M
EcoR1 Capital, LLC
2,15%
$10.6M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora